ARTICLE | Clinical News
Besivance besifloxacin ophthalmic solution regulatory update
June 8, 2009 7:00 AM UTC
Bausch & Lomb said FDA approved an NDA for Besivance besifloxacin 0.06% ophthalmic suspension to treat bacterial conjunctivitis. An FDA advisory committee voted unanimously to recommend approval of th...